

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1-18 (canceled).

Claim 19 (previously presented): A method of providing an adjuvant effect to a vaccine comprising at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence comprising combining said antigen or in vivo generator with a surfactant or with a mixture of surfactants having an overall HLB number of between 5 and 15 and comprising:

- (i) ethoxylated derivatives of ester of fatty acids having 12 to 22 carbon atoms with sorbitan or mannitan having a number of EOs of between 1 and 60; or
- (ii) ethoxylated derivatives of oils having a number of EOs of between 1 and 60.

Claim 20 (original): A method of providing an adjuvant effect to a vaccine as defined in Claim 19, wherein said vaccine does not include an oily phase.

Claims 21-29 (canceled).

Claim 30 (original): The method as defined in Claim 19, wherein said vaccine is suitable for a mucosal vaccination.

Claim 31 (original): The method as defined in Claim 30, wherein said vaccine is suitable for application orally, nasally, rectally or vaginally.

Claim 32 (cancelled).

Claim 33 (currently amended): The method of claim 19, wherein said surfactant or said mixture of surfactants comprises:

- ethoxylated derivatives of mannitan oleate having a number of EOs of between 5 and 15;
- ethoxylated derivates of corn oil having a number of EOs between 20 and 40 ~~corn oil~~; or
- ethoxylated derivatives of castor oil having a number of EOs equal to 7 or equal to 60.

Claim 34 (cancelled).